Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

  title={Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients},
  author={Bonaventura Casanova and Laura Lacruz and Mar{\'i}a Luisa Villar and Jos{\'e} Andr{\'e}s Dom{\'i}nguez and M Gadea and Francisco Gasc{\'o}n and Javier Jose Mallada and David Herv{\'a}s and Mar{\'i}a Sim{\'o}-Castell{\'o} and Jos{\'e} C. {\'A}lvarez-cerme{\~n}o and Carmen Calles and Javier Olascoaga and Llu{\'i}s Rami{\'o}-Torrent{\'a} and Carmen Alcal{\'a} and Angeles Cervell{\'o} and Isabel Bosc{\'a} and Francisco Carlos P{\'e}rez-Mirallles and Francisco Coret},
  journal={Neurological Sciences},
ObjectiveTo study the efficacy of interferon beta (IFNβ) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS).MethodThis is an observational, multicenter and retrospective study with prospectively collected data of patients that started treatment with IFNβ or GA. Treatment decision was made blinded to the OCMB status. Time to first attack after starting therapy was compared by using Kaplan… 
Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis
The combined evidence from the current literature suggests that intrathecal IgM is a negative prognostic marker that identifies patients with CIS who have a higher risk of converting to CDMS and patients with relapsing–remitting MS (RRMS) with aHigher risk of a more aggressive disease course.
Role of B Cells in Multiple Sclerosis and Related Disorders
This concise review recaps current concepts underlying the biology and therapeutic rationale behind B‐cell–directed therapeutics in MS, and proposes strategies to optimize the use of existing anti–B‐cell treatments and provide future directions for research in this area.
Potential Pathological Biomarkers in Multiple Sclerosis
This review discusses several promising serum and cerebrospinal fluid biomarkers and imaging biomarkers used in clinical practice and sheds light on the criteria and the challenges a biomarker faces to be considered as a standard one.
Reader response: Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis
It is demonstrated that intrathecal oligoclonal IgM bands (OCMB) were a risk factor for early conversion to MS2 and also for increase in T2 lesions and early brain atrophy on magnetic resonance.
Reader response: An observational study on quality of life and preferences to sustain life in locked-in state
The finding of a good subjective quality of life (QoL) in patients with ALS in locked-in state (LIS) confirms the previous results, but the need to gain more distinctive insights into the psychologic adaptation process underlying such outcomes in future work is stressed.
Disputes & Debates: Editors’ Choice
This exchange highlights the important points of debate in the field of rTMS regarding the most reliable means of targeting deeper structures in the brain, and conversely, identifying the responsible structural mediators of observed stimulation effects.


Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis
Results from this study indicate that users of GA have a significantly lower probability of 2- year relapse than users of IFN beta-1b, and among continuous users, the 2-year total average direct medical costs are significantly lower for users ofGA than for usersof IFNbeta.
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
The purpose of this systematic review is to summarise available evidence on the comparative effectiveness of IFNs-beta and GA on disease course through the analysis of head-to-head trials and suggest that relapse rates were higher in the group given IFNs than in the GA group at 36 months.
Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)
The results provide helpful clinical information regarding the efficacy of immunomodulatory therapies in early stages of RRMS patients in a clinical setting and some limitations of the study design are provided.
Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis
The presence of lipid-specific immunoglobulin M bands in CSF predicts a more adverse long-term outcome in patients with MS; it may define a subset of patients who might benefit from aggressive treatment during the early phase of the disease.
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Influence of oligoclonal IgM specificity in multiple sclerosis disease course
Data corroborate that anti-lipid OCMB associate with an aggressive MS course and show that OCMB that do not recognize myelin lipids represent a transient immune response related to a more benign disease course.